Literature DB >> 28079346

Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication.

David Y Graham1, Sharmila Fagoonee2, Rinaldo Pellicano3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28079346     DOI： 10.23736/S1121-421X.17.02369-8

Source DB:  PubMed          Journal:  Minerva Gastroenterol Dietol        ISSN： 1121-421X


× No keyword cloud information.
  8 in total

1.  Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.

Authors:  Jie Pan; Zhengchao Shi; Dingsai Lin; Ningmin Yang; Fei Meng; Lang Lin; Zhencheng Jin; Qingjie Zhou; Jiansheng Wu; Jianzhong Zhang; Youming Li
Journal:  Front Med       Date:  2020-01-03       Impact factor: 4.592

2.  Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells.

Authors:  Hanyi Song; Long Zhou; Dongyan Liu; Lihui Ge; Yan Li
Journal:  Exp Ther Med       Date:  2019-07-05       Impact factor: 2.447

Review 3.  Helicobacter pylori diagnosis and therapy in the era of antimicrobial stewardship.

Authors:  Akiko Shiotani; Priya Roy; Hong Lu; David Y Graham
Journal:  Therap Adv Gastroenterol       Date:  2021-12-21       Impact factor: 4.409

4.  Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.

Authors:  Xiaoqiong Tang; Zhonghua Wang; Yalin Shen; Xiaona Song; Mohammed Benghezal; Barry J Marshall; Hong Tang; Hong Li
Journal:  BMC Microbiol       Date:  2022-08-13       Impact factor: 4.465

5.  Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy.

Authors:  Peiwei Li; Jing Jin; Yan Chen; Jianjuan Ma; Qin Du; Yuehua Han
Journal:  Front Microbiol       Date:  2022-09-07       Impact factor: 6.064

6.  Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori.

Authors:  Lei Li; FanDong Meng; Shengtao Zhu; ShuiLong Guo; YongJun Wang; Xin Zhao; YiLin Sun; Yan Zhang; QinQin Wang; HuFeng Xu; ShuTian Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-05       Impact factor: 2.629

7.  Comment #2 on "First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin".

Authors:  Davide Giuseppe Ribaldone; Marco Astegiano
Journal:  Gastroenterol Res Pract       Date:  2018-12-16       Impact factor: 2.260

8.  Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections.

Authors:  Chia-Jung Kuo; Chun-Wei Chen; Puo-Hsien Le; Jun-Te Hsu; Cheng-Yu Lin; Hao-Tsai Cheng; Ming-Yao Su; Chun-Jung Lin; Cheng-Tang Chiu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-05       Impact factor: 4.802
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.